|
Genetic Determinants of Ankylosing Spondylitis Severity Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Genetic Determinants of Ankylosing Spondylitis Severity conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Genetic Determinants of Ankylosing Spondylitis Severity Clinical research trials and Genetic Determinants of Ankylosing Spondylitis Severity medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Genetic Determinants of Ankylosing Spondylitis Severity. Genetic Determinants of Ankylosing Spondylitis Severity Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Genetic Determinants of Ankylosing Spondylitis Severity clinical trial. Subjects typically recieve the finest healthcare available for their Genetic Determinants of Ankylosing Spondylitis Severity condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Determinants of Ankylosing Spondylitis Severity  Genetic Determinants of Ankylosing Spondylitis Severity
Genetic Determinants of Ankylosing Spondylitis Severity
For Condition: Ankylosing Spondylitis
Status: Recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: This study will explore how genes-units of heredity-may influence the severity of ankylosing spondylitis. It will examine whether some genes may cause people with ankylosing spondylitis to have more rapid fusion of the bones of the spine, more difficulty performing daily activities, or be more likely to need joint surgery. Patients who developed ankylosing spondylitis after age 16 and have had the disease for 20 years or more may be eligible for this study. The onset of disease is dated to the first appearance of symptoms of inflammatory low back pain or restricted spinal motion. Patients with a spondyloarthropathy other than AS may not enroll. Participants will complete a brief medical history and physical exam. They will fill out a 30-minute questionnaire that includes questions on demographics (such as age, ethnicity, marital status, etc.), medication history, work history, hip surgeries, and assessment of functional disability. Fifty milliliters (about 3-1/3 tablespoons) of blood will be drawn for gene testing, and X-rays will be taken of the pelvis, lower back, and neck, if recent X-rays (within 1 year) are not available. Women of childbearing age will have a urine pregnancy test before having X-rays.
Details: The susceptibility to ankylosing spondylitis (AS) is largely genetically determined. Recent studies suggest that the severity of AS is also influenced to a large extent by genetic factors. The goal of this study is to identify genes that influence the severity of AS. We hypothesize that genetic markers of susceptibility, including human leukocyte antigen (HLA) polymorphisms, are among the genes that also influence the severity of AS. Other genes that could potentially influence the severity of AS include those that affect the severity of joint inflammation and those that influence bone formation. In this cross-sectional study, we will test the association of HLA markers and polymorphisms in several genes involved in the regulation of inflammation and bone formation with the severity of AS in 400 patients. Each patient will have had AS for at least 20 years. Measures of AS severity will be the extent of spinal fusion as measured radiographically, functional disability, time to permanent work disability, and need for total hip arthroplasty. Identifying genetic markers that are associated with differences in the severity of AS will greatly enhance our understanding of the pathogenesis of this disease by suggesting mechanisms and pathways involved in the development of long-term damage. In a separate but related protocol, we will assess genetic markers associated with persistent active inflammation in patients with AS.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Participants will: 1. have been diagnosed with AS by the modified New York criteria 2. have had AS for 20 years or more. The duration of AS will be dated from the time of onset of symptoms of inflammatory low back pain or restricted spinal motion 3. be able to read English. EXCLUSION CRITERIA: Potential participants will be excluded if: 1. onset of AS was at age 16 or younger 2. have a spondyloarthropathy other than AS 3. are unable to provide informed consent.
Total Enrollment: 100
Location and Contact Information:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030130; 03-AR-0130
Study Start Date: March 20, 2003
Record last reviewed: February 19, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056849
Other Ankylosing Spondylitis Studies:
1. Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
2. Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis
3. Prevention of Arthritis-Related Work Disability
4. Genetics of Ankylosing Spondylitis
5. Genetic Determinants of Ankylosing Spondylitis Severity
Related Studies:
Other Ankylosing Spondylitis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Genetic Determinants of Ankylosing Spondylitis Severity
|
|
|
|
|
|
|
|
